High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is
the most common and deadliest type of ovarian cancer. HGSC appears to arise from the …

The fallopian tube secretory cell is the cell of origin for the majority of ovarian cancers.
Although it remains unclear what triggers neoplastic transformation of these cells, certain …

Financial Disclosure Prof. Menon has stock ownership and has received research funding
from Abcodia Ltd, a UCL spinout company with an interest in biomarkers and commercial …

Background The cost-effectiveness of population-based panel testing for high-and moderate-
penetrance ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We …

Background The presence of deleterious mutations in breast cancer 1 gene (BRCA1) or
breast cancer 2 gene (BRCA2) significantly increases the risk of developing some cancers …

Purpose Cancer screening strategies have commonly adopted single-biomarker thresholds
to identify abnormality. We investigated the impact of serial biomarker change interpreted …

OBJECTIVE: The objective of this study is to compare ovarian function and surgical
outcomes between patients affected by benign uterine pathologies submitted to total …

OBJECTIVE: Prophylactic bilateral salpingo-oophorectomy is advised for women with BRCA
mutations, but there are adverse consequences of premature menopause. The majority of …

Importance Moving to multigene testing for all women with breast cancer (BC) could identify
many more mutation carriers who can benefit from precision prevention. However, the cost …

Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA
carriers who can benefit from screening/prevention. We estimate the cost-effectiveness of …